BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
BCI
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, July 14, 2026
Home
»
Newsletters
» BioWorld
BioWorld
May 29, 2009
View Archived Issues
Exelixis Shares Soar on $1B Cancer Drug Deal with Sanofi
If all goes according to plan, Exelixis Inc. could bank more than $1 billion under a new licensing and discovery deal with Sanofi-Aventis Group for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. (BioWorld Today)
Read More
Phase II Trial Update Triggers Wild Ride for Peregrine Shares
Read More
'Finished' Mouse Genome Is Still a Work in Progress
Read More
As Markets Brighten, Medivation Seeks $65.8M in Shares Offering
Read More
Neuropharm Revives Autism Drug, Rises on Partner Talks
Read More
Amylin 'Back to Business' Following Contentious Vote
Read More
Other News To Note
Read More
Clinic Roundup
Read More
